CRBN and cancer: In conjunction with the findings by Van Nguyen et al. [37] that VCP/p97 link glutamine metabolism with the immunomodulatory drug target CRBN, our data further highlight VCP/p97 as a promising anticancer drug target that may be particularly important in ‘glutamine-addicted’ [76] cancers.